On 6 November 2025, the US Centers for Medicare & Medicaid Services (CMS) announced the GENEROUS (GENErating cost Reductions fOr US Medicaid) […]
The Department of Health, Disability and Ageing has announced changes to their PBS Notice of Intent (NOI) process that will impact your […]
Key challenges and opportunities shaping health technology assessment Next Tuesday’s ISPOR workshop brings together Australia’s leading HTA stakeholders: PBAC members, HTA Review […]
What we’re seeing We’ve been working with some remarkable Australian digital health companies lately. These are teams with genuinely impressive clinical evidence […]
Staying ahead in the pharma and medtech sectors requires a deep understanding of regulatory and advisory timelines, such as those set by […]
Australia is a leader in niche life science segments with strong global markets, including plasma therapies, hearing implants, and sleep apnoea devices. […]
Pulse Economics is offering free 30-minute consultations to help you navigate the complexities of market access and reimbursement in Australia. Gain insights […]
In today’s rapidly evolving healthcare landscape, navigating the reimbursement pathway for high-cost highly specialised therapies presents a formidable challenge. These treatments, including […]
It’s a busy time for sustainability in healthcare: This critical topic is gaining traction in health policy, the MedTech industry, hospitals, and […]
Ever asked for feedback? The results can often be quite surprising. We might find ourselves pondering questions like, “Why did they focus […]
